Eli Lilly Upgraded to Buy at Berenberg on Obesity Drug Leadership, Pipeline Strength

Berenberg has upgraded its rating on Eli Lilly (LLY) to Buy, setting a new price target of $1,400 per share. The revised target, detailed in a note to investors on Tuesday, suggests a potential upside of nearly 25% from current levels, driven by the firm's confidence in the drugmaker's ability to extend its lead in the lucrative obesity treatment market.

Analyst Cites R&D and Pipeline

According to Berenberg analyst Kerry Holford, the firm's analysis confirms Eli Lilly's track record of delivering "best-in-class returns" on its research and development investments. The note stated that investor expectations for Lilly are high, but the analyst is confident in the company's prospects and believes its pipeline, which is being funded by the success of its obesity drugs, is currently "underappreciated."

Holford highlighted that the success of drugs like Zepbound and Mounjaro is fueling significant external investment. The note mentioned that Lilly has committed approximately $60 billion across more than 25 deals this year to bolster its pipeline.

Key Growth Drivers

Berenberg's bullish thesis rests on several key factors that are expected to drive future growth for Eli Lilly. The analyst pointed to the company's established leadership in both obesity and diabetes markets and identified several catalysts on the horizon.

Ad

Key points from the analyst note include:

• Established Market Leaders: Zepbound and Mounjaro are considered dominant products in the obesity and diabetes sectors, respectively.
• Oral GLP-1 Drug: The imminent diabetes approval of an oral GLP-1 drug, referred to as Foundayo, is expected to "unlock significant demand."
• Pipeline Diversification: Recent acquisitions are expanding Lilly's focus into new therapeutic areas. The note cited the roughly $4 billion purchase of AtaiBeckley for psychedelic assets in mental health and the $8 billion acquisition of Centessa to enter the sleep-wake disorder market.

Valuation Justified by Growth

While acknowledging Eli Lilly's premium valuation, Berenberg argued that it is justified. The stock trades at 23.4 times estimated 2027 earnings, significantly higher than the global pharmaceutical peer average of 13.6 times.

Holford concluded that the company's superior growth profile, the breadth of its drug pipeline, and its high research productivity warrant the significant premium. The firm also sees potential upside to Eli Lilly's 2026 financial guidance.